The number of patients with heart failure worldwide nearly doubled from 33.5 million in 1990 to 64.3 million in 2017. That's the finding of a study published today in the European Journal of Preventive Cardiology, a journal ...
Feb 12, 2021
2
86
Medical histories of patients collected and stored in electronic health records (EHR) can be rapidly leveraged to predict the probability of death from COVID-19, information that could prove valuable in managing limited therapeutic ...
Feb 4, 2021
0
5
Cardiovascular disease is the leading cause of death in patients with type 2 diabetes, and youth with severe obesity and type 2 diabetes face a high risk of developing cardiovascular disease during their lifetime. However, ...
Dec 10, 2020
0
2
An analysis of Geisinger's electronic health records has revealed chronic kidney disease to be the leading risk factor for hospitalization from COVID-19.
Dec 2, 2020
0
12
Women face a 20% increased risk of developing heart failure or dying within five years after their first severe heart attack compared with men, according to new research published today in the American Heart Association's ...
Nov 30, 2020
1
32
Researchers have identified a new druggable target for heart failure in neonates and infants, a condition for which there has been no specific treatment. Approximately 60 percent of children born with congenital heart abnormalities ...
Nov 19, 2020
0
2
A novel patient engagement tool led one in five patients with heart failure to a more effective treatment regimen of generic medications, according to late-breaking research presented today at the American Heart Association's ...
Nov 17, 2020
0
2
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking ...
Nov 17, 2020
0
4
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way. Since that time, evidence in favor of the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors ...
Nov 17, 2020
0
18
Omecamtiv mecarbil, a new, investigational heart medication, reduced the risk of heart failure-related events in patients with heart failure with reduced ejection fraction, according to late-breaking research presented today ...
Nov 13, 2020
0
3
